Analysis of the Effcacy and Safety of Amivantamab in Non-small Cell Lung Cancer 
Patients with EGFR/MET Gene Abnormalities: A Single Center’s Experience

Conclusion Amivantamab was effective in Chinese NSCLC patients with EGFR exon 20 insertion and post-Osimertinib EGFR-mutant patients, similar to the results of clinical trials conducted in western countries. Amivantamab was well tolerated and emphases should be put on adverse events such as rash, paronychia, and infusion-related reactions. 
 DOI: 10.3779/j.issn.1009-3419.2022.102.26
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research